Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and Company Issues Voluntary Nationwide Recall of One Lot of GLUCAGON® Emergency Kit Due to Loss of Potency

09/24/2021 | 08:04pm EDT

Eli Lilly and Company announced that it is voluntarily recalling lot D239382D, Expiration April 2022, of Glucagon Emergency Kit for Low Blood Sugar (Glucagon for Injection, 1 mg per vial; Diluent for Glucagon, 1 mL syringe), to the consumer/user level. Lilly is recalling lot D239382D to the patient level because of a product complaint reporting that the vial of Glucagon was in liquid form instead of the powder form. The firm's investigation indicates that the liquid in this Glucagon vial could be related to the manufacturing process. The use of the liquid form of this product may fail to treat severe low blood sugar due to loss of potency. Risk Statement: Severe hypoglycemia in patients with diabetes, if not reversed, can potentially cause adverse health consequences ranging from transient, minor complaints to neurological damage, seizures, and even death if not promptly treated. Associated with the one product complaint, it was reported to Lilly that the involved patient experienced lack of drug effect and also reported subsequent seizures. Glucagon Emergency Kit is used as an anti-hypoglycemic agent and a gastrointestinal motility inhibitor indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus. The product is packaged in a kit containing 1mg of freeze-dried (lyophilized) product in a 3 mL vial and a pre-filled diluent syringe. The affected Glucagon Emergency Kit lot is D239382D and the expiration date is April 2022 (label expiry date: 04 2022). The lot number can be found on the label of the kit as well as the vial (refer to the photos provided). The lot was distributed nationwide to wholesalers and retailers. Lilly is notifying its distributors and customers by written communication and is arranging for return and replacement of all recalled products. Wholesalers and Distributors with an existing inventory of Glucagon Emergency Kit lot D239382D should cease distribution and quarantine the product immediately.


© S&P Capital IQ 2021
All news about ELI LILLY AND COMPANY
10/20ELI LILLY AND : FCA And AKS Claim Founded On Free Pharmaceutical Product Education Dismiss..
AQ
10/19ELI LILLY AND : Tirzepatide results published in The Lancet show superior A1C and body wei..
PR
10/19Eli Lilly and Company Provides Tirzepatide Results
CI
10/18ELI LILLY AND : Declares Q4 Dividend of $0.85 a Share, Payable Dec. 10 to Shareholders of ..
MT
10/18ELI LILLY AND : Lilly Declares Fourth-Quarter 2021 Dividend
PR
10/18Eli Lilly and Company Declares Dividend for the Fourth Quarter of 2021, Payable on Dece..
CI
10/14ELI LILLY AND : Releases Updated Data From Phase 3 Breast Cancer Trial
MT
10/14ELI LILLY AND : Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Dat..
PR
10/14Eli Lilly and Company Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial ..
CI
10/13AGILENT TECHNOLOGIES : Eli Lilly Get FDA's OK for Assay to Identify Early Breast Cancer
MT
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2021 27 366 M - -
Net income 2021 6 489 M - -
Net Debt 2021 11 548 M - -
P/E ratio 2021 34,1x
Yield 2021 1,35%
Capitalization 221 B 221 B -
EV / Sales 2021 8,50x
EV / Sales 2022 8,24x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 243,75 $
Average target price 269,42 $
Spread / Average Target 10,5%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY42.84%218 640
JOHNSON & JOHNSON3.83%430 148
ROCHE HOLDING AG15.79%339 425
PFIZER, INC.16.27%240 303
NOVO NORDISK A/S56.55%239 079
MERCK & CO., INC.-0.77%205 472